---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061105"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:06:09.488701+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences reports Q3 net loss $14.4M; partnership with Gilead provides $100M upfront

## Summary
- Net loss $14.4M ($0.27/sh) vs $23.1M ($0.48/sh) in Q3 2022.
- R&D expenses fell to $10.8M from $18.1M YoY due to trial completions and pipeline discontinuations.
- Cash $46.2M at Sep 30; $100M upfront from Gilead in Oct extends cash runway into 2H 2025.
- Partnership with Gilead includes opt-in rights on current/future pipeline; Gilead contributed two herpesvirus programs.
- Appointed Anuj Gaggar, MD, PhD as CMO; expects four development candidates in clinic by end 2024.

## SEC filing metadata
- accession: 0000950170-23-061105
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017023061105/0000950170-23-061105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017023061105/asmb-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061105
- JSON: https://secwatch.observer/filing/0000950170-23-061105.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061105.txt

## Key facts
- Earnings Releases
  ASSEMBLY BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income Net loss attributable to common stockholders was $14.4 million, or $0.27 per basic and diluted share.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net loss attributable to common stockholders was $14.4 million, or $0.27 per basic and diluted share
  - Result: reported results
  source text: Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000095017023061105/0000950170-23-061105-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.